Inhaled pentamidine plus oral miltefosine for mucosal leishmaniasis
Treatments studied
Part of Infections, Skin clinical trials.
This trial tests a combination of two medicines—inhaled pentamidine and oral miltefosine—to treat mucosal leishmaniasis, a parasitic infection of the nose, mouth, and throat. It may be an option for people in Bolivia who have not been treated recently.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 12 years old or older.
- You weigh more than 45 kg (about 99 pounds).
- You have leishmaniasis that affects your nose, mouth, throat, or voice box, confirmed by a lab test or a skin test plus a scar and living in an area where the disease exists.
- You have not had any leishmaniasis treatment in the last 12 months (unless that treatment ended more than 12 months ago and your disease has not improved in the last 6 months).
- You do not have other serious health problems that could interfere with the treatment.
- If you are a woman of childbearing age, you must use two forms of birth control for 5 months after starting treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if oral medicines can treat cutaneous (skin) or mucosal leishmaniasis in people aged 60 and older. It compares two different pills to find a safer, easier option for elderly patients.
This trial tests how well miltefosine works for people with leishmaniasis, a skin infection from a parasite. It aims to find the best way to use this medicine to help patients get better.
This study tests different drugs to find which works best for cutaneous leishmaniasis (a skin infection from a parasite). It may help people with many or large sores, or sores in sensitive areas like near the eyes or nose.
This study tests a gel form of miltefosine applied directly to skin sores caused by leishmaniasis. It is for adults with mild to moderate skin infections who have not already tried and failed other treatments.
This study tests two new oral medicines compared to an existing oral medicine for people with a first episode of cutaneous leishmaniasis (skin sores caused by a parasite). It aims to find a more effective and convenient treatment.
This trial compares two approaches for treating skin sores caused by Leishmania: standard injections alone versus injections plus a laser treatment. It aims to see if adding laser therapy improves healing.
Hear when a new Mucosal Leishmaniasis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.